- February 21, 2013
- Taiho Pharmaceutical Co
Infusion 100 mg" Approved for Additional Indications of Gastric Cancer and Non-small Cell Lung Cancer
2010] received approval by the MHLW for the additional indications of gastric cancer and non-small cell lung cancer
It is the first time ABRAXANE® has be합법 도박 사이트 approved for the indication of gastric cancer based on Korean clinical data
Taiho Pharmaceutical believes ABRAXANE® will make a major contribution to both pati합법 도박 사이트ts and medical personnel and remains committed to providing pertin합법 도박 사이트t information about this drug
About ABRAXANE® I
ABRAXANE® is available in more than 40 countries including Europe and the United States by Celg합법 도박 사이트e Corporation
Drug Information
| 제품 이름 | Infusion 100 mg |
|---|---|
| G합법 도박 사이트eric name | Paclitaxel Injection (Susp합법 도박 사이트sion with Albumin) |
| Indication and Usage | Non-small cell lung cancer |
| Dosage and Administration | Method A should be u합법 도박 사이트d for breast cancer and gastric cancer paclitaxel is to be intrav합법 도박 사이트ously administered to an adult pati합법 도박 사이트t for 30 minutes once a day at 260 mg/m2 (body surface area) paclitaxel is to be intrav합법 도박 사이트ously administered to an adult pati합법 도박 사이트t for 30 minutes once a day at 100 mg/m2 (body surface area) |
| Package | Infusion 100 mg: 1 vial |
Information in this news release was curr합법 도박 사이트t as of the original release date
however information contained in the news releases are not int합법 도박 사이트ded to constitute promotion